Genzyme sues Sandoz for infringing Hectorol patent

WILMINGTON, Del., May 25 (BestGrowthStock) – Genzyme Corp (GENZ.O: )
has sued Sandoz Inc, accusing it of infringing the patent for
its Hectorol drug which is approved for controlling hormone
production in patients with kidney disease.

In a lawsuit filed in Delaware District Court, Genzyme said
that Sandoz, a unit of Swiss drugmaker Novartis AG (NOVN.VX: ),
had applied to the Food and Drug Administration for an
abbreviated new drug application to make a generic form of
doxercalciferol, the chemical name for Hectorol.

Genzyme, of Cambridge, Massachusetts, was issued a patent
in 1997 for its Hectorol drug to lower the parathyroid hormone
in patients suffering from kidney disease, according to the
complaint, which was filed on Friday.

Genzyme asked the court to block Sandoz from making or
selling a generic form of Hectorol until its patent expires.

The case is Genzyme Corp v Sandoz Inc, U.S. District Court,
District of Delaware, No. 10-00429.

Stocks

(Reporting by Tom Hals, editing by Dave Zimmerman)

Genzyme sues Sandoz for infringing Hectorol patent